Healthcare of Ontario Pension Plan Trust Fund Purchases Shares of 578,500 ADMA Biologics, Inc. (NASDAQ:ADMA)

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 578,500 shares of the biotechnology company’s stock, valued at approximately $6,468,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. LSV Asset Management bought a new stake in ADMA Biologics during the first quarter valued at about $1,028,000. Seven Eight Capital LP bought a new stake in ADMA Biologics during the second quarter valued at about $1,992,000. BNP Paribas Financial Markets raised its holdings in ADMA Biologics by 152.2% during the first quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock valued at $4,837,000 after acquiring an additional 442,315 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of ADMA Biologics by 90.7% in the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock worth $7,717,000 after purchasing an additional 556,175 shares during the last quarter. Finally, Inspire Investing LLC increased its holdings in shares of ADMA Biologics by 125.2% in the first quarter. Inspire Investing LLC now owns 189,303 shares of the biotechnology company’s stock worth $1,249,000 after purchasing an additional 105,256 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

ADMA has been the topic of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. Mizuho lifted their target price on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Finally, HC Wainwright lifted their target price on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, August 12th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $15.50.

ADMA Biologics Trading Up 3.7 %

Shares of NASDAQ ADMA opened at $20.29 on Friday. The business’s 50 day moving average is $17.02 and its two-hundred day moving average is $11.87. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80. ADMA Biologics, Inc. has a 1-year low of $3.06 and a 1-year high of $20.58. The stock has a market capitalization of $4.70 billion, a P/E ratio of -1,014.50 and a beta of 0.62.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm had revenue of $107.20 million for the quarter, compared to analysts’ expectations of $86.44 million. During the same quarter in the prior year, the firm posted ($0.02) earnings per share. The company’s quarterly revenue was up 78.4% on a year-over-year basis. As a group, research analysts expect that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Insider Buying and Selling

In related news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Young Kwon sold 60,000 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares of the company’s stock, valued at $4,408,712.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 466,900 shares of company stock valued at $8,224,121 over the last quarter. 3.70% of the stock is owned by corporate insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.